公开(公告)号：EP1086076A1

公开(公告)日：2001-03-28

申请号：EP99928769.1

申请日：1999-06-17

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： SHERRILL, Ronald George,Glaxo Wellcome Inc. ,  HALE, Michael, R. ,  SPALTENSTEIN, Andrew,Glaxo Wellcome Inc. ,  FURFINE, Eric Steven,Glaxo Wellcome Inc. ,  ANDREWS, Clarence W., III,Glaxo Wellcome Inc. ,  LOWEN, Gregory, Thomas

IPC分类号： C07C303/00

CPC分类号： C07D213/30 ,  C07C311/48 ,  C07C311/49 ,  C07C2601/08 ,  C07C2601/14 ,  C07D215/48 ,  C07D235/06 ,  C07D235/26 ,  C07D235/30 ,  C07D235/32 ,  C07D241/42 ,  C07D243/04 ,  C07D265/02 ,  C07D277/30 ,  C07D307/20 ,  C07D309/06 ,  C07D309/12 ,  C07D309/22 ,  C07D319/06 ,  C07D401/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/06 ,  C07D417/12 ,  C07D493/04 ,  C07F9/6561

摘要： The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.